EP3096833A1 - Directional subintimal access for chemical agent delivery - Google Patents
Directional subintimal access for chemical agent deliveryInfo
- Publication number
- EP3096833A1 EP3096833A1 EP15701874.8A EP15701874A EP3096833A1 EP 3096833 A1 EP3096833 A1 EP 3096833A1 EP 15701874 A EP15701874 A EP 15701874A EP 3096833 A1 EP3096833 A1 EP 3096833A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- housing
- delivery member
- sections
- penetrating member
- delivery
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/0043—Catheters; Hollow probes characterised by structural features
- A61M25/0054—Catheters; Hollow probes characterised by structural features with regions for increasing flexibility
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/0067—Catheters; Hollow probes characterised by the distal end, e.g. tips
- A61M25/0082—Catheter tip comprising a tool
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/01—Introducing, guiding, advancing, emplacing or holding catheters
- A61M25/06—Body-piercing guide needles or the like
- A61M25/0662—Guide tubes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0069—Devices for implanting pellets, e.g. markers or solid medicaments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/0067—Catheters; Hollow probes characterised by the distal end, e.g. tips
- A61M25/0082—Catheter tip comprising a tool
- A61M2025/0095—Catheter tip comprising a tool being one or more needles protruding from the distal tip and which are not used for injection nor for electro-stimulation, e.g. for fixation purposes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/01—Introducing, guiding, advancing, emplacing or holding catheters
- A61M25/06—Body-piercing guide needles or the like
- A61M25/0662—Guide tubes
- A61M2025/0681—Systems with catheter and outer tubing, e.g. sheath, sleeve or guide tube
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/04—Liquids
- A61M2202/0468—Liquids non-physiological
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2210/00—Anatomical parts of the body
- A61M2210/12—Blood circulatory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/0067—Catheters; Hollow probes characterised by the distal end, e.g. tips
- A61M25/0068—Static characteristics of the catheter tip, e.g. shape, atraumatic tip, curved tip or tip structure
- A61M25/007—Side holes, e.g. their profiles or arrangements; Provisions to keep side holes unblocked
Definitions
- the present disclosure generally relates to the treatment and prevention of occlusions within tubular organs, and more specifically, to the delivery of chemical agent(s) to vascular tissue to inhibit restenosis.
- Restenosis or the re -narrowing of a blood vessel, is not an uncommon occurrence following the treatment of an initial vascular occlusion, and may lead to restricted blood flow within the blood vessel.
- Known techniques for inhibiting the formation of vascular occlusions include the delivery of anti-restenotic agents, and typically involve the placement of an implanted device within the lumen of a blood vessel to do so.
- a stent, or other such structure may be coated with the anti-restenotic agent, and implanted within the lumen of the vessel such that the anti-restenotic agent is eluted into the tissue comprising the wall of the vessel over time.
- Such techniques and structures typically deliver the anti-restenotic agent to the intimal layer of the vessel wall along the entire periphery of the vessel wall, and are limited in their efficacy due to the nature of the tissue comprising the intimal layer.
- a delivery member for use in delivering a chemical agent to tissue.
- the delivery member includes a body including a plurality of discrete, separable sections, which may be identical in configuration. Each section of the body includes a housing defining an internal cavity, and a penetrating member that extends from the housing.
- the housing includes first and second opposing ends.
- the first end of the housing includes an opening, and the penetrating member extends from the second end.
- the penetrating member is configured to facilitate passage of the delivery member through the tissue, and may be incisive in configuration.
- the plurality of sections are configured and dimensioned such that an applied tensile force separates adjacent sections.
- the plurality of sections includes a first section with a first housing having an opening formed therein, and a first penetrating member extending from the first housing, as well as a second section with a second housing having an opening formed therein, and a second penetrating member extending from the second housing.
- the first penetrating member is positioned within the second housing, and the opening in the second housing defines a transverse cross-sectional dimension smaller than a maximum transverse cross-sectional dimension defined by the first penetrating member.
- the first and second sections may be formed from a resilient material such that a tensile force applied to the delivery member causes the first penetrating member and/or the opening in the second housing to deform, and thereby permit the first penetrating member to be withdrawn from the second housing to separate the first and second sections.
- the plurality of sections further includes a third section with a third housing having an opening formed therein, and a third penetrating member extending from the third housing, and a fourth section with a fourth housing having an opening formed therein, and a fourth penetrating member extending from the fourth housing.
- the third penetrating member is positioned within the fourth housing, and the opening in the fourth housing defines a transverse cross-sectional dimension smaller than a maximum transverse cross-sectional dimension defined by the third penetrating member.
- the third and fourth sections may be formed from a resilient material such that the tensile force applied to the delivery member causes the third penetrating member and/or the opening in the fourth housing to deform, and thereby permit the third penetrating member to be withdrawn from the fourth housing to separate the third and fourth sections.
- additional sections may be included to form a delivery member of an appropriate length.
- a system for use in treating a blood vessel that includes a guide catheter that is insertable into a lumen of the blood vessel, and a delivery member.
- the guide catheter defines an internal passageway, and the delivery member is insertable into the internal passageway of the guide catheter.
- the delivery member includes a plurality of discrete, separable sections, each of which includes an anti-restenotic agent, and may be identical in configuration.
- Each section includes a housing that defines an internal cavity, as well as a penetrating member extending from the housing that is configured to facilitate passage of the delivery member through tissue, e.g., a wall of the blood vessel.
- the plurality of sections are configured and dimensioned such that a tensile force applied to the delivery member separates adjacent sections.
- the plurality of sections of the delivery member includes a first section with a first housing having an opening formed therein, and a first penetrating member extending from the first housing, and a second section with a second housing having an opening formed therein, and a second penetrating member extending from the second housing.
- the first penetrating member is positioned within the second housing, and the opening in the second housing defines a transverse cross-sectional dimension smaller than a maximum transverse cross-sectional dimension defined by the first penetrating member.
- the first and second sections may be formed from a resilient material such that a tensile force applied to the delivery member causes the first penetrating member and/or the opening in the second housing to deform, and thereby permit the first penetrating member to be withdrawn from the second housing to separate the first and second sections.
- the plurality of sections of the delivery member further includes a third section with a third housing having an opening formed therein, and a third penetrating member extending from the third housing, and a fourth section with a fourth housing having an opening formed therein, and a fourth penetrating member extending from the fourth housing.
- the third penetrating member is positioned within the fourth housing, and the opening in the fourth housing defines a transverse cross- sectional dimension smaller than a maximum transverse cross-sectional dimension defined by the third penetrating member.
- the third and fourth sections may be formed from a resilient material such that the tensile force applied to the delivery member causes the third penetrating member and/or the opening in the fourth housing to deform, and thereby permit the third penetrating member to be withdrawn from the fourth housing to separate the third and fourth sections.
- a method of performing an endovascular procedure includes inserting a guide catheter into a lumen of a blood vessel, advancing a delivery member through the guide catheter, deploying the delivery member from the guide catheter such that the delivery member is positioned between adjacent tissue layers forming a wall of the blood vessel, and delivering a chemical agent between the adjacent tissue layers forming the wall of the blood vessel.
- delivering the chemical agent includes depositing a portion of the delivery member between the adjacent tissue layers, e.g., by separating a first section of the delivery member from a second section of the delivery member, and withdrawing a remaining portion of the delivery member from the blood vessel.
- the portion of the delivery member deposited between the adjacent tissue layers forming the wall of the blood vessel will degrade over time, whereby the chemical agent is released into the tissue of the blood vessel.
- delivering the chemical agent includes communicating the chemical agent into an internal channel extending through the delivery member, and through a plurality of radial openings formed in the delivery member that are in communication with the internal channel. Additionally, or alternatively, the chemical agent may be delivered through an open distal end of the delivery member.
- delivering the chemical agent includes delivering first and second compounds into the internal channel extending through the delivery member, wherein at least one of the first and second compounds includes the chemical agent. When brought into contact with each other, the first and second compounds combine to form a solid, biodegradable filament that is positioned between the adjacent tissue layers forming the wall of the blood vessel.
- FIG. 1 is a partial cross-sectional illustration of an exemplary blood vessel.
- FIG. 2 illustrates a system for use in treating a blood vessel that includes a guide catheter, and a delivery member including a plurality of discrete, separable sections that is insertable into the guide catheter.
- FIG. 3 is a partial longitudinal, cross-sectional view illustrating the guide catheter positioned within the blood vessel, and the delivery member positioned within the guide catheter, during the course of a surgical procedure.
- FIG. 4 is a longitudinal, cross-sectional view of one of the sections comprising the delivery member.
- FIG. 5 is an enlargement of the area of detail identified in FIG. 2.
- FIG. 6 is a partial longitudinal, cross-sectional view illustrating a portion of the delivery member deposited within the tissue of the blood vessel following withdrawal of the guide catheter.
- FIG. 7 is a rear, perspective view illustrating a section of the delivery member according to an alternate embodiment of the disclosure.
- FIG. 8 is a rear, perspective view illustrating a section of the delivery member according to an alternate embodiment of the disclosure.
- FIG. 9 is a partial longitudinal, cross-sectional view illustrating an alternate method of using the delivery member in conjunction with a stent.
- FIG. 10 illustrates an alternate embodiment of the delivery member shown in communication with a source including a chemical agent.
- FIG. 11 illustrates the delivery member of FIG. 10, and an alternate embodiment of the source of the chemical agent.
- FIG. 12 is a partial longitudinal, cross-sectional view illustrating the delivery member of FIGS. 10 and 11 during the course of a surgical procedure in which a biodegradable filament is formed and deposited within the tissue of the blood vessel.
- FIG. 13 illustrates an alternate embodiment of the delivery member of the present disclosure.
- FIG. 14 is a partial longitudinal, cross-sectional view illustrating the delivery member of FIG. 13 positioned within the tissue of the blood vessel during the course of a surgical procedure.
- FIG. 15 is a partial longitudinal, cross-sectional view illustrating an alternate embodiment of the guide catheter during delivery of the delivery member.
- FIG. 16 is a side view illustrating an alternate embodiment of the guide catheter seen in FIG. 15.
- FIG. 17 is a side view illustrating another embodiment of the guide catheter.
- the term "patient” refers to a human or animal patient
- the term “clinician” refers to a doctor, nurse, support personnel, or other care provider.
- occlusion refers to any partial or total blockage of a hollow anatomical structure, e.g., a tubular organ, such as a blood vessel. While the devices, systems, and methodologies described herein are discussed in the context of a vascular procedure, the principles of the present disclosure are equally applicable to other surgical procedures concerning the treatment of a hollow anatomical structure. Examples of such procedures include, but are not limited to, cardiac procedures, abdominal procedures, urinary procedures, and intestinal procedures.
- FIG. 1 provides a cross-sectional illustration of a blood vessel V that is obstructed by an occlusion O.
- the blood vessel V includes a lumen L defined by a vessel wall W that is comprised of an intimal layer I, a medial layer M, and an adventitial layer A.
- FIGS. 2 and 3 illustrate a system 1000 (FIG. 2) for use in an exemplary medical procedure in which a chemical agent is delivered to the tissue forming the vessel wall W (FIGS. 1, 3) of the blood vessel V.
- the system 1000 includes a guide catheter 100, and a delivery member 200 that is insertable into, and movable through, the guide catheter 100.
- the guide catheter 100 is inserted into the lumen L of the blood vessel V, and is advanced through the lumen L until the guide catheter 100 is positioned proximate to the occlusion O.
- the delivery member 200 is then advanced through the guide catheter 100 into the tissue comprising the vessel wall W to facilitate the delivery of the chemical agent.
- Suitable chemical agents include anti-restenotic agents, such as, for example, paclitaxel, sirolimus, and/or a cholesterol degrading enzyme.
- the delivery member 200 is advanced from the guide catheter 100, and passed through the intimal layer I of the vessel wall W into the subintimal space, i.e., the tissue beneath the intimal layer I.
- the delivery member 200 is inserted into the tissue comprising the medial layer M.
- the efficacy of the chemical agent can be increased compared to the efficacy achieved in other delivery locations, e.g., the intimal layer I.
- the efficacy of the chemical agent, and the procedure as a whole, is further increased by the directional delivery facilitated by the guide catheter 100, which allows a specific area or section of the vessel wall W to be treated, e.g., the section of the vessel wall W immediately adjacent the occlusion O, rather than the entire circumference of the vessel wall W.
- the guide catheter 100 is configured and dimensioned for insertion into the lumen
- FIG. 1 A suitable guide catheter 100 is the ECHELON TM Micro Catheter, which is made available by Covidien.
- the guide catheter 100 includes a body 102 (FIG. 2) with a tubular wall 104 defining an internal passageway 106 that is configured and dimensioned to accommodate insertion and movement of the delivery member 200 therethrough.
- a port 108 is formed in the body 102, and is dimensioned to permit the delivery member 200 to exit the passageway 106 therethrough in order to facilitate directional deployment of the delivery member 200.
- the orientation of the port 108, and thus, deployment of the delivery member 200 can be regulated by the clinician in order to permit the delivery member to enter the tissue comprising the vessel wall W (FIGS. 1, 3) in a precise location.
- the port 108 is illustrated as extending radially through the wall 104 in FIGS. 2 and 3, the port 108 may be formed at a distal end 110 of the guide catheter 100, and extend outwardly therefrom towards the occlusion O, without departing from the scope of the present disclosure. Additionally, although illustrated as including a single port 108 only, alternate configurations of the guide catheter 100 may include one or more additional ports 108.
- the delivery member 200 (FIGS. 2, 3) includes a body 202 that is configured and dimensioned for insertion into, and movement through, the internal passageway 106 of the guide catheter 100.
- the body 202 includes a plurality of individual sections 204 that are separable from one another in a manner discussed below.
- the sections 204 are illustrated as forming the entirety of the body 202 of the delivery member 200. In alternate configurations of the delivery member 200, however, the sections 204 may form only a portion of the body 202 of the delivery member 200, e.g., an end portion of the body 202.
- the sections 204 are formed from a material that is at least partially resilient, such as, for example, silicone and/or fabric materials, or a synthetic resin, for example, polyurethane, polyethylene, polypropylene, nylons, polytetrafluoroethylene (PTFE), polyether ether ketone (PEEK), polyimide, combinations thereof, and the like, or from a non-biodegradable material, such as polyesters, e.g., polyalkyl terephthalates, polyamides, e.g., nylon, polyurethanes, polycarbonates, fluorooplymers, polyolefms, vinyl polymers, combinations thereof, and the like.
- the sections 204 may be formed through any suitable method of manufacture, including, but not limited to, injection molding, or laser machining.
- Each section 204 includes a housing 206 (FIGS. 4, 5) having opposing end portions 208, 210, and a penetrating portion 212 that extends from an end wall 214 at the end portion 210. In order to reduce manufacturing costs and complexity, each of the sections 204 may be formed as identical structures. [0047]
- the housing 206 includes an outer wall 216 with an opening 218 formed in the end portion 208 that defines a transverse cross-sectional configuration "Ti" (FIG. 4).
- the outer wall 216 of each housing 206 defines an internal cavity 220 that is configured and dimensioned to accommodate the penetrating portion 212 of an adjacent section 204, as seen in FIG. 5.
- the penetrating portion 212 defines a maximum transverse cross-sectional configuration "T 2 " (FIG. 4) that is larger than the transverse cross-sectional configuration "Ti" defined by the opening 218, and includes a distal tip 222 that is configured and dimensioned to facilitate passage of the penetrating portion 212 through tissue, e.g., the tissue comprising the vessel wall W (FIG. 1) of the vessel V.
- tissue e.g., the tissue comprising the vessel wall W (FIG. 1) of the vessel V.
- the distal tip 222 of the penetrating portion 212 may include an incisive configuration, as illustrated in FIG. 4, for example. In alternate configurations of the delivery member 200, however, the distal tip 222 may include a more rounded, blunt configuration.
- Each of the sections 204 is configured and dimensioned to support and sustain a compressive load, e.g., a force applied in the direction of arrow 1 in FIG. 5, and yield to a tensile load, e.g., a force applied in the direction of arrow 2 in FIG. 5.
- a compressive load e.g., a force applied in the direction of arrow 1 in FIG. 5
- a tensile load e.g., a force applied in the direction of arrow 2 in FIG. 5.
- the applied compressive load may force the penetrating portion 212 of one section 204 into contact with an inner surface 224 of the internal cavity 220 of an adjacent section 204.
- an exemplary method of using the delivery member 200 includes positioning the guide catheter 100 adjacent the occlusion O in the vessel V, as illustrated in FIG. 3, and orienting the guide catheter 100 such that the port 108 is directed towards a desired point of entry into the vessel wall W.
- the system 1000 FIG. 2
- either an antegrade approach or a retrograde approach may be employed in positioning the guide catheter 100.
- the delivery member 200 is deployed through the port 108 (FIGS. 2, 3), and follows the natural dissection plane of the blood vessel V such that the delivery member 200 is passed through the intimal layer I into the medial layer M.
- the guide catheter 100 remains in place to assist in stabilization of the delivery member 200.
- the delivery member 200 is manipulated until the delivery member 200 spans the occlusion O such that at least one of the sections 204 comprising the body 202 of the delivery member 200 is positioned proximate each end ⁇ 0 ⁇ , ⁇ 02 of the occlusion O (FIG. 3). A tensile load is then applied to the delivery member 200 in order to separate adjacent sections 204 of the body 202.
- the delivery member 200 will tend to separate adjacent the port 108, i.e., the point at which the drag force transitions, thereby allowing the clinician to control the number of sections 204 that are deposited within the tissue comprising the vessel wall W.
- one or more of the sections 204 of the delivery member 200 may include one or more surface irregularities.
- sections 204' are disclosed that include one or more barbs 205 ', each of which has a pointed apex 205A'.
- sections 204" are disclosed that include one or more scales 205", each of which has a rounded end portion 205A".
- the surface irregularities e.g., the barbs 205' (FIG. 7) and/or the scales 205" (FIG. 8), may be either uniformly distributed across the outer surface of the sections 204', 204", as illustrated in FIGS. 7 and 8, or randomly distributed across the outer surface of the sections 204', 204".
- the guide catheter 100 may include a cutting or heating element (not shown) adjacent the port 108.
- the guide catheter 100 and/or the delivery member 200 may include radiopaque materials or portions, such as markers 226 (FIG. 2), which may be visualized under fluoroscopy.
- the delivery member 200 e.g., the individual sections 204
- the delivery member 200 may be formed from a nonbiodegradable material, such as polyesters, e.g., polyalkyl terephthalates, polyamides, e.g., nylon, polyurethanes, polycarbonates, fluorooplymers, polyolefms, vinyl polymers, combinations thereof, and the like, and coated with the chemical agent, thereby permitting absorption of the chemical agent by the tissue comprising the medial layer M upon contact with the sections 204.
- a nonbiodegradable material such as polyesters, e.g., polyalkyl terephthalates, polyamides, e.g., nylon, polyurethanes, polycarbonates, fluorooplymers, polyolefms, vinyl polymers, combinations thereof, and the like
- the delivery member 200 since the delivery member 200 is initially concealed within the guide catheter 100, wash-off of the chemical agent is inhibited, as is dilution by the tissue.
- the delivery member 200 e.g., the individual sections 204, may be formed a biodegradable base material, into which the chemical agent may be incorporated.
- the sections 204 may be formed from a base material including homopolymers, copolymers, and/or blends possessing glycolide, lactide, p-dioxanone, ⁇ -caprolactone, trimethylene carbonate, orthoesters, phosphoesters, polysaccharides, modified starches, cellulose, oxidized cellulose, glycolide and lactide based polymers, such as poly-lactide-co-glycolide (PLGA) copolymers, and various combinations of the foregoing, and the chemical agent may be mixed into the base material during manufacture.
- PLGA poly-lactide-co-glycolide
- the guide catheter 100 Following successful deployment of the sections 204, and delivery of the chemical agent, the guide catheter 100, as well as the remaining portion of the delivery member 200, can be retracted and withdrawn from the patient.
- the aforedescribed procedure may be used in conjunction with another surgical procedure, such as, for example, a procedure in which a thrombectomy catheter is employed to create an opening in the occlusion O (FIGS. 1, 9) in order to facilitate the placement of a stent S (FIG. 9).
- the delivery member 200 may be inserted directly into, and deposited within, the tissue comprising the occlusion O.
- sections 204 of the delivery member 200 may be inserted into the medial layer M so as to span the stent S, i.e., such that at least one section 204 comprising the body 202 of the delivery member 200 is positioned proximate each end E S i, E S2 of the stent S.
- FIG. 10 illustrates an additional embodiment of the presently disclosed delivery member, which is identified by the reference character 300.
- the delivery member 300 includes a body 302 that is configured and dimensioned for insertion into, and movement through, the internal passageway 106 (FIG. 2) of the guide catheter 100.
- the body 302 includes an open distal end 304, and defines an internal channel 306.
- the delivery member 300 following placement of the guide catheter 100 within the vessel V, e.g., in the manner illustrated in FIG. 3, the delivery member 300 is deployed from the guide catheter 100, and passed through the intimal layer I into the medial layer M in the manner discussed above. Thereafter, the chemical agent is communicated into the internal channel 306 extending through the body 302 of the delivery member 300 from a source 400 (FIG. 10), such as a pump, syringe, or the like. The chemical agent is expelled through the open distal end 304 of the body 302, and delivered directly to the medial layer M.
- a source 400 such as a pump, syringe, or the like.
- first and second compounds are delivered into the internal channel 306 extending through the body 302 from a source 400' (FIGS. 11, 12).
- the first and second agents may include first and second hydrogel precursors, such as polymers, functional polymers, macromolecules, small molecules, or crosslinkers that can take part in a reaction to form a network of crosslinked molecules, e.g., a hydrogel.
- the source 400' may be any device suitable for the intended purpose of delivering first and second compounds, and maintaining separation of the first and second compounds until delivery.
- the first and second compounds combine and solidify to form a biodegradable filament 600 (FIG. 12) containing the chemical agent in situ, i.e., within the vessel wall W, and more particularly, within the medial layer M.
- the filament 600 can thus be extruded into the medial layer M from the delivery member 300, or alternatively, the filament 600 can be formed within the internal channel 306 extending through the body 302 of the delivery member 300, and the delivery member 300 can be withdrawn over the filament 600.
- the delivery member 300 can be manipulated within the medial layer M, e.g., advanced, retracted, and/or rotated.
- the guide catheter 100, and the delivery member 300 can be retracted and withdrawn from the patient.
- FIGS. 13 and 14 illustrate another embodiment of the delivery member, which is identified by the reference character 700.
- the delivery member 700 is identical to the delivery member 300 (FIGS. 11, 12), but for the differences discussed below.
- the delivery member 700 includes a body 702 having a closed distal end 704, and defining an internal channel 706.
- tissue e.g., the tissue comprising the vessel wall W (FIG. 14)
- the closed distal end 704 of the body 702 may include a tapered configuration, as illustrated in FIGS. 13 and 14.
- the body 702 includes one or more radial openings 708, e.g., perforations, in communication with the internal channel 706 that permit the communication of fluid, such as the aforedescribed chemical agent(s), from the internal channel 706 externally of the delivery member 700.
- fluid such as the aforedescribed chemical agent(s
- the delivery member 700 is deployed from the guide catheter 100, and passed through the intimal layer I into the medial layer M (FIG. 14). Thereafter, the chemical agent is communicated into the internal channel 706 extending through the body 702 of the delivery member 700, e.g., from the source 400. Upon communication into the internal channel 706, the chemical agent is expelled from the delivery member 700 through the radial opening(s) 708, and is delivered directly to the medial layer M.
- the delivery member 700 can be manipulated within the medial layer M, e.g., advanced, retracted, and/or rotated, to achieve delivery of the chemical agent to the any desired portion of the medial layer M.
- the guide catheter 100, and the delivery member 700 can be retracted and withdrawn from the patient.
- a guide catheter 800 is described for delivery of the delivery member, e.g., the delivery member 200 (FIG. 2).
- the guide catheter 800 includes a body 802 that facilitates directed delivery of the delivery member 200 through an open distal end 804 thereof via the incorporation of a bend 806.
- the guide catheter 800 may be configured and dimensioned to achieve any offset required by a particular procedure.
- the bend 806 may achieve an offset of approximately 45°, as illustrated in FIG. 15, an offset of 75°, as illustrated in FIG. 16, or any other acute or obtuse angle required by the particular procedure in which the guide catheter 800 is employed, e.g., an offset of approximately 90°.
- the guide catheter 800 is positioned within the vessel V such that the body 802 is positioned in contact with the wall W of the vessel, and the bend 808 is positioned approximately opposite the desired point of entry into the medial layer M. Thereafter, a delivery member, e.g., the delivery member 200 (FIGS. 2, 15), is inserted into the guide catheter 800, and the delivery member 200 is advanced through the distal end 804 of the guide catheter 800, through the intimal layer I, and into the medial layer M proximally of the occlusion O, as discussed above.
- a delivery member e.g., the delivery member 200 (FIGS. 2, 15)
- FIG. 17 illustrates another embodiment of the catheter, which is identified by the reference character 900.
- the guide catheter 800 is illustrated in FIGS. 15 and 16 as including a single bend, i.e., the bend 806, the guide catheter 900 includes multiple bends.
- the guide catheter 900 includes a first bend 908 extending in a first direction, and a second bend 910 extending in a second, opposite direction to thereby collectively achieve an offset of approximately 90°.
- the curvature of the bends 908, 910 may be varied, e.g., in direction and/or magnitude, to achieve any required degree of offset.
- the guide catheter 900 may include a greater number of bends, e.g., three or four bends, to further adjust the offset of the guide catheter 900.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Anesthesiology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biophysics (AREA)
- Pulmonology (AREA)
- Medical Informatics (AREA)
- Dermatology (AREA)
- Media Introduction/Drainage Providing Device (AREA)
- Surgical Instruments (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14/162,945 US10213581B2 (en) | 2014-01-24 | 2014-01-24 | Directional subintimal access for chemical agent delivery |
| PCT/US2015/010804 WO2015112351A1 (en) | 2014-01-24 | 2015-01-09 | Directional subintimal access for chemical agent delivery |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP3096833A1 true EP3096833A1 (en) | 2016-11-30 |
| EP3096833B1 EP3096833B1 (en) | 2020-04-08 |
Family
ID=52434975
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP15701874.8A Active EP3096833B1 (en) | 2014-01-24 | 2015-01-09 | Directional subintimal access for chemical agent delivery |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US10213581B2 (en) |
| EP (1) | EP3096833B1 (en) |
| JP (1) | JP6576935B2 (en) |
| WO (1) | WO2015112351A1 (en) |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4697575A (en) * | 1984-11-21 | 1987-10-06 | Henry Ford Hospital | Delivery system for interstitial radiation therapy including substantially non-deflecting elongated member |
| US4936823A (en) * | 1988-05-04 | 1990-06-26 | Triangle Research And Development Corp. | Transendoscopic implant capsule |
| US5017381A (en) | 1990-05-02 | 1991-05-21 | Alza Corporation | Multi-unit pulsatile delivery system |
| US5312456A (en) * | 1991-01-31 | 1994-05-17 | Carnegie Mellon University | Micromechanical barb and method for making the same |
| US6888998B1 (en) * | 1994-11-28 | 2005-05-03 | Sony Corporation | Data recording and reproducing apparatus having a data transferring device for selectively transferring data between multiple data recording and reproducing devices |
| US6080099A (en) * | 1998-08-12 | 2000-06-27 | Syntheon, Llc | Radioactive therapeutic seeds |
| US6997951B2 (en) * | 1999-06-30 | 2006-02-14 | Edwards Lifesciences Ag | Method and device for treatment of mitral insufficiency |
| AU2002239290A1 (en) | 2000-11-20 | 2002-06-03 | Senorx, Inc. | Tissue site markers for in vivo imaging |
| US20040158118A1 (en) | 2003-02-10 | 2004-08-12 | Drobnik Christopher D. | Terminus-spacer component of a string comprising one or more spacer components and one or more implantation seeds |
| WO2007053823A2 (en) * | 2005-10-31 | 2007-05-10 | Biolucent, Inc. | Brachytherapy apparatus and methods of using same |
| JP2010503490A (en) * | 2006-09-15 | 2010-02-04 | ボストン サイエンティフィック リミテッド | Endoprosthesis with adjustable surface features |
| WO2009097468A2 (en) | 2008-01-29 | 2009-08-06 | Kliman Gilbert H | Drug delivery devices, kits and methods therefor |
| ES2395371T3 (en) | 2010-01-08 | 2013-02-12 | Clifford T. Solomon | Bioinjection device |
| CN102740800A (en) * | 2010-01-29 | 2012-10-17 | 爱尔康医药有限公司 | Biodegradable protrusions on inflatable device |
| US8679093B2 (en) | 2010-11-23 | 2014-03-25 | Microchips, Inc. | Multi-dose drug delivery device and method |
| CA2827956C (en) | 2011-02-23 | 2019-05-07 | Ams Research Corporation | Drug releasing pelvic treatment system and method |
| EP2846707A4 (en) | 2012-05-04 | 2016-11-30 | Interventco Llc | Device and method for filling of aneurysm or body cavity |
| US10039656B2 (en) * | 2013-06-05 | 2018-08-07 | Abbott Cardiovascular Systems Inc. | Coupled scaffold segments |
-
2014
- 2014-01-24 US US14/162,945 patent/US10213581B2/en active Active
-
2015
- 2015-01-09 EP EP15701874.8A patent/EP3096833B1/en active Active
- 2015-01-09 WO PCT/US2015/010804 patent/WO2015112351A1/en not_active Ceased
- 2015-01-09 JP JP2016547905A patent/JP6576935B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2017503601A (en) | 2017-02-02 |
| US10213581B2 (en) | 2019-02-26 |
| EP3096833B1 (en) | 2020-04-08 |
| WO2015112351A1 (en) | 2015-07-30 |
| US20150209548A1 (en) | 2015-07-30 |
| JP6576935B2 (en) | 2019-09-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11224528B2 (en) | Stent | |
| US9913969B2 (en) | Devices for delivering substances through an extra-anatomic opening created in an airway | |
| US11173058B2 (en) | Stent | |
| EP1988960B1 (en) | System and method for treating a vascular condition | |
| US9533128B2 (en) | Devices for maintaining patency of surgically created channels in tissue | |
| US8002740B2 (en) | Devices for maintaining patency of surgically created channels in tissue | |
| US7815590B2 (en) | Devices for maintaining patency of surgically created channels in tissue | |
| CN103974676B (en) | Utilize under the inner membrance of biological absorbable support the most logical | |
| US20130297007A1 (en) | Apparatuses and methods for guiding endoluminal devices through body lumens | |
| JP2021000478A (en) | Stent | |
| US10213581B2 (en) | Directional subintimal access for chemical agent delivery | |
| JP2020512883A (en) | Delivery system for stents with protruding features | |
| CN113924067A (en) | Support with anti-moving device | |
| US20230302263A1 (en) | Removable dual function loading tool & protector for drug coated medical devices | |
| JP2025509978A (en) | Tissue manipulation systems and methods of use | |
| HK1259722A1 (en) | Stent | |
| HK1259722B (en) | Stent | |
| WO2017209766A1 (en) | Stent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20160704 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| AX | Request for extension of the european patent |
Extension state: BA ME |
|
| DAX | Request for extension of the european patent (deleted) | ||
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
| 17Q | First examination report despatched |
Effective date: 20190104 |
|
| GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
| INTG | Intention to grant announced |
Effective date: 20191115 |
|
| GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
| GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
| AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 1253505 Country of ref document: AT Kind code of ref document: T Effective date: 20200415 Ref country code: CH Ref legal event code: EP |
|
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602015050200 Country of ref document: DE |
|
| REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
| REG | Reference to a national code |
Ref country code: NL Ref legal event code: MP Effective date: 20200408 |
|
| REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG4D |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200808 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200408 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200708 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200709 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200817 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200408 Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200408 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200408 |
|
| REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 1253505 Country of ref document: AT Kind code of ref document: T Effective date: 20200408 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200408 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200408 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200408 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200708 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200408 |
|
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602015050200 Country of ref document: DE |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200408 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200408 Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200408 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200408 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200408 Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200408 Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200408 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200408 |
|
| PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200408 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200408 |
|
| 26N | No opposition filed |
Effective date: 20210112 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200408 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200408 |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
| GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20210109 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210109 |
|
| REG | Reference to a national code |
Ref country code: BE Ref legal event code: MM Effective date: 20210131 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210131 Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210109 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210131 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210131 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20150109 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200408 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200408 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200408 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200408 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20251218 Year of fee payment: 12 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IE Payment date: 20251218 Year of fee payment: 12 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20251217 Year of fee payment: 12 |